Jeffrey T. Guptill

Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study

James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · The Lancet Neurology · 2017 · 745 citations

Multicentre Study, Pharmacology, Medicine +3

Anti‐musk antibody myasthenia gravis: Clinical findings and response to treatment in two large cohorts

Jeffrey T. Guptill, Donald B. Sanders, Amelia Evoli · Muscle & Nerve · 2011 · 375 citations

A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial

Raffael Nachbagauer, Jodi Feser, Abdollah Naficy et al. · Nature Medicine · 2020 · 342 citations · Full text

Vaccination, Cross-protection, Vaccine Development +10

Density and Distribution of Hippocampal Neurotransmitter Receptors in Autism: An Autoradiographic Study

Gene J. Blatt, Claudia M. Fitzgerald, Jeffrey T. Guptill et al. · Journal of Autism and Developmental Disorders · 2001 · 317 citations

Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study

James F. Howard, Saskia Bresch, Angela Genge et al. · The Lancet Neurology · 2023 · 213 citations

Medicine, Surgery, Clinical Trials +1